Literature DB >> 1767944

Co-fluorescence of europium and samarium in time-resolved fluorimetric immunoassays.

Y Y Xu1, I Hemmilä, V M Mukkala, S Holttinen, T Lövgren.   

Abstract

In the presence of an excess of Y3+, the fluorescence intensities of Eu3+ and Sm3+, chelated with benzoyltrifluoroacetone (BTA) or thenoyltrifluoroacetone (TTA) in an aqueous solution containing 1,10-phenanthroline, were increased by factors ranging from 209- to 811-fold. This co-fluorescence phenomenon was used in a highly sensitive time-resolved fluorimetric detection of the lanthanides, Eu3+ and Sm3+. The detection limits of Eu3+ in the BTA- and TTA-based solutions were 4 and 15 fmol dm-3, respectively. The detection limits of Sm3+ were 0.11 and 0.12 pmol dm-3, respectively. The co-fluorescence enhancement systems were also applied in the double-label time-resolved fluorimetric immunoassay of luteinizing hormone and follicle stimulating hormone using specific antibodies labelled either with Eu3+ or Sm3+. The co-fluorescence enhancement solution was superior as compared with the commercial 'direct' fluorescence enhancement solution based on the acidic solution of beta-naphthoyltrifluoroacetone, trioctylphosphine oxide and Triton X-100, in respect to the signal level obtained and the sensitivity. It is suited to time-resolved fluorimetric immunoassays in which particularly high detection sensitivities are required, and it can also be used in double-label assays employing Eu3+ and Sm3+ chelate labels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1767944     DOI: 10.1039/an9911601155

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  2 in total

1.  Membrane interactions influence the peptide binding behavior of DR1.

Authors:  M A Sherman; H A Runnels; J C Moore; L J Stern; P E Jensen
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

2.  An insulin peptide that binds an alternative site in class II major histocompatibility complex.

Authors:  S M Tompkins; J C Moore; P E Jensen
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.